4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

S-8 - SeaStar Medical Holding Corp (0001831868) (Filer)

8-K - SeaStar Medical Holding Corp (0001831868) (Filer)

8-K/A - SeaStar Medical Holding Corp (0001831868) (Filer)

8-K - SeaStar Medical Holding Corp (0001831868) (Filer)

424B3 - SeaStar Medical Holding Corp (0001831868) (Filer)

10-Q - SeaStar Medical Holding Corp (0001831868) (Filer)

SCHEDULE 13G/A - SeaStar Medical Holding Corp (0001831868) (Subject)

8-K - SeaStar Medical Holding Corp (0001831868) (Filer)

EFFECT - SeaStar Medical Holding Corp (0001831868) (Filer)

SCHEDULE 13G - SeaStar Medical Holding Corp (0001831868) (Subject)

Sponsors educational summit of leading pediatric AKI health care experts Announces best practices webinar to further advance new treatment options DENVER, July 14, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that it is a proud sponsor of key initiatives to advance the treatment of pediatric patients with acute kidney injury (AKI). AKI is a major driver of critical illness, prolonged hospital stays, and high mortality rates. Despite its massive impact on patient outcomes, significant gap

Enables standardized inpatient hospital billing for QUELIMMUNE® (SCD-PED) therapy Universal code paves the way for billing of future potential SCD therapies requiring renal replacement therapy DENVER, June 23, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that its Selective Cytopheretic Device (SCD) therapy has received dedicated ICD-10-PCS (International Classification of Diseases, 10th Revision, Procedure Coding System) codes from the Centers for Medicare & Medicaid Services (CMS). This assi

DENVER, June 22, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, announced today that Eric Schlorff, Chief Executive Officer of SeaStar Medical, will present at the Virtual Investor Summit Conference on Wednesday, June 24th at 10:30 am Eastern Time. Interested investors can register and view the live presentation here: SeaStar Medical Events / Presentations A replay of the SeaStar Medical presentation will be available on the Company's website and can be accessed here. The replay will be available for up to 30

Added 7 top-rated children's hospitals to QUELIMMUNE® pediatric acute kidney injury (AKI) customer base, increasing first quarter revenue 69% versus first quarter 2025 revenue Advanced enrollment in the NEUTRALIZE-AKI pivotal clinical trial in adult patients with AKI Initiated efforts for the submission of a modular post-marketing application (PMA) Webcast today at 4:30 pm Eastern Time DENVER, May 13, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today financial results for the three months ended Marc

DENVER, May 06, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its first quarter financial results after market close on Wednesday, May 13, 2026, and host a webcast and conference call to discuss its financial results and business progress. Date/Time:Wednesday, May 13, 2026, at 4:30 p.m. ET / 2:30 p.m. MT Webcast:The live webcast and replay can be found here. Register for the call:Preregistration is required to attend the live call and can be accessed here. A pin code and dial i

Results from pediatric patients in the SAVE Registry shows no device-related adverse events or immunosuppression and continued strong survival data  In vitro analysis of the SeaStar Medical SCD indicates modulation of the immune response, shifting monocytes towards an anti-inflammatory, reparative phenotype SeaStar Medical hosts an industry symposium and panel discussion focused on innovation in the treatment of pediatric AKI, supporting its emerging leadership in this community DENVER, March 30, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ fai

Added top-rated children's hospitals to QUELIMMUNE™ pediatric Acute Kidney Injury (AKI) customer base Completed enrollment in FDA-mandated QUELIMMUNE SAVE Post-Marketing Registry Exceeded 50% enrollment milestone in pivotal trial of SCD therapy in adult patients with AKI Advanced pipeline indications with initiation of cardio-renal clinical trial Webcast today at 4:30 pm Eastern Time DENVER, March 25, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today financial results for the three months and yea

DENVER, March 18, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its fourth quarter and year-end 2025 financial results after market close on Wednesday, March 25, 2026, and host a webcast and conference call to discuss its financial results and business progress. Date/Time:Wednesday, March 25, 2026, at 4:30 p.m. ET / 2:30 p.m. MT  Webcast:The live webcast and replay can be found here.  Register for the call:Preregistration is required to attend the live call and can be accessed h

NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that presentations from the Life Sciences Virtual Investor Forum, held March 11th – 12th, are now available for on-demand viewing. The forum featured CEO chats and company presentations from leadership teams representing innovative companies across the biotechnology, medical device, and pharmaceutical sectors, offering investors insights into emerging technologies, strategic initiatives, and growth opportunities within the life sciences industry. REGISTER AND VIEW PRESENTATIONS HERE The presentations will be available 24/7 for 90 days. Investors,

NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place March 11–12, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams. Schedule 1x1 meetings here "We are delighted to highlight today's innovators from the Life Science

DENVER, May 06, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its first quarter financial results after market close on Wednesday, May 13, 2026, and host a webcast and conference call to discuss its financial results and business progress. Date/Time:Wednesday, May 13, 2026, at 4:30 p.m. ET / 2:30 p.m. MT Webcast:The live webcast and replay can be found here. Register for the call:Preregistration is required to attend the live call and can be accessed here. A pin code and dial i

Added top-rated children's hospitals to QUELIMMUNE™ pediatric Acute Kidney Injury (AKI) customer base Completed enrollment in FDA-mandated QUELIMMUNE SAVE Post-Marketing Registry Exceeded 50% enrollment milestone in pivotal trial of SCD therapy in adult patients with AKI Advanced pipeline indications with initiation of cardio-renal clinical trial Webcast today at 4:30 pm Eastern Time DENVER, March 25, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today financial results for the three months and yea

DENVER, March 18, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its fourth quarter and year-end 2025 financial results after market close on Wednesday, March 25, 2026, and host a webcast and conference call to discuss its financial results and business progress. Date/Time:Wednesday, March 25, 2026, at 4:30 p.m. ET / 2:30 p.m. MT  Webcast:The live webcast and replay can be found here.  Register for the call:Preregistration is required to attend the live call and can be accessed h

Business highlights include: Three new top-rated children's hospitals adopt QUELIMMUNE therapy for ultra-rare pediatric Acute Kidney Injury (AKI)Commercial use of QUELIMMUNE therapy demonstrates positive survival results as reported from the QUELIMMUNE SAVE Surveillance RegistryNew clinical sites added to expand adult NEUTRALIZE-AKI pivotal trial enrollmentStrengthened the balance sheet, raising $12.4 million to fund future operationsWebcast call today at 4:30 p.m. Eastern Time DENVER, Nov. 13, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure

DENVER, Nov. 05, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its third quarter financial results after market close on Thursday, November 13, 2025, and host a webcast and conference call to discuss its financial results and business progress. Date/Time:Thursday, November 13, 2025, at 4:30 p.m. ET / 2:30 p.m. MTWebcast:The live webcast and replay can be found here.Dial-in number:To join the conference call via phone, please pre-register online here to receive a telephone number

DENVER, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its first quarter financial results after market close on Wednesday, August 13, 2025, and host a webcast and conference call to discuss its financial results and business progress. Date/Time:Wednesday, August 13, 2025, at 4:30 p.m. ET / 2:30 p.m. MTWebcast:The live webcast and replay can be found here.Conference ID:2078693Dial-in numbers:1 (800) 715-9871 within the U.S.1 (646) 307-1963 from outside the U.S.

DENVER, May 07, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its first quarter financial results after market close on Wednesday, May 14, 2025, and host a webcast and conference call to discuss its financial results and business progress. Date/Time:Wednesday, May 14, 2025, at 4:30 p.m. ET / 2:30 p.m. MTWebcast:The live webcast and replay can be found here.Conference ID:2078693Dial-in numbers:1 (800) 715-9871 within the U.S. 1 (646) 307-1963 from outside the U.S.   A rep

DENVER, March 27, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today financial results for the three months and year ended December 31, 2024, and provided business updates on key initiatives. "Our significant accomplishment in 2024 position us well for a transformational year in 2025," said Eric Schlorff, SeaStar Medical CEO. "Last year, we not only received our first product approval for QUELIMMUNE and began our commercial launch, but we added 14 new clinical sites for our NEUTRALIZE AKI pivotal clinic

DENVER, March 24, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its fourth quarter and year-end 2024 financial results after market close on Thursday, March 27, 2025, and host a webcast and conference call to discuss its financial results and business progress. Date/Time:Thursday, March 27, at 4:30 p.m. ET / 1:30 p.m. PT  Webcast:The live webcast and replay can be found here.  Conference ID:2078693  Dial-in numbers:1 (800) 715-9871 within the U.S.   1 (646) 307-1963 from outside

U.S. total addressable market for five initial indications is $25 to $33 billion REMINDER: Business Update Conference Call begins at 4:30 p.m. Eastern time today DENVER , Dec. 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, estimates a U.S. total addressable market for its proprietary, patented Selective Cytopheretic Device (SCD) in five clinical indications, subject to U.S. Food & Drug Administration (FDA) approvals, of $25 to $33 billion. The following chart summarizes ranges of the adult SCD total addressable market

DENVER, Nov. 17, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that Michael Messinger, a seasoned healthcare executive with over 25 years of industry experience, has joined SeaStar Medical as Chief Financial Officer. "Mike brings to SeaStar Medical a breadth of financial expertise, operational discipline, and strategic healthcare experience that will be invaluable as we grow our commercial operations and prepare for additional commercial opportunities for our SCD therapy," stated Eric Schlorff, CE

SC 13G - SeaStar Medical Holding Corp (0001831868) (Subject)